Unresectable

Oncology·MeSH: Neoplasms

105 drugs in development·43 companies·1 clinical trial

Drug Pipeline by Phase

Approved(16)

Drug	Company
afinitor	Novartis AG (NVS)
amtagvi	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
braftovi	ARRAY BIOPHARMA INC (ARRY)
docetaxel	Amneal Pharmaceuticals, Inc. (AMRX)
eribulin	DR REDDYS LABORATORIES LTD (RDY)
keytruda qlex	Merck & Co., Inc. (MRK)
KIMMTRAK	Immunocore Holdings plc (IMCR)
mekinist	Novartis AG (NVS)
mektovi	ARRAY BIOPHARMA INC (ARRY)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
tecelra	Adaptimmune Therapeutics PLC (ADAP)
trodelvy	Immunome Inc. (IMNM)
tukysa	Seagen Inc. (SGEN)
Zenocutuzumab (Zeno) / BIZENGRI® (zenocutuzumab-zbco)	Merus N.V. (MRUS)
ziihera	Zymeworks Inc. (ZYME)
Ziihera	Jazz Pharmaceuticals plc (JAZZ)

Phase 3(31)

Drug	Company
acasunlimab	Genmab A/S (GMAB)
amezalpat	Tempest Therapeutics, Inc. (TPST)
Avelumab	Merck & Co., Inc. (MRK)
Dacarbazine	Filana Therapeutics Inc. (FLNA)
Dacarbazine	ENANTA PHARMACEUTICALS INC (ENTA)
Datopotamab Deruxtecan	Merus N.V. (MRUS)
Erbitux®	Amneal Pharmaceuticals, Inc. (AMRX)
folinic acid	Merus N.V. (MRUS)
IMA203	Merus N.V. (MRUS)
IMA203	PTC THERAPEUTICS, INC. (PTCT)
IMA203	Filana Therapeutics Inc. (FLNA)
IMA203	ENANTA PHARMACEUTICALS INC (ENTA)
Lartesertib	Merck & Co., Inc. (MRK)
leucovorin	BeOne Medicines Ltd. (ONC)
Leucovorin	BeOne Medicines Ltd. (ONC)
lifileucel	PTC THERAPEUTICS, INC. (PTCT)
lifileucel	Filana Therapeutics Inc. (FLNA)
lifileucel	Merus N.V. (MRUS)
lifileucel	ENANTA PHARMACEUTICALS INC (ENTA)
pemetrexed	Crinetics Pharmaceuticals, Inc. (CRNX)
pemigatinib	Incyte Corp. (INCY)
Rescue Medication	Merus N.V. (MRUS)
RPH-002	Amneal Pharmaceuticals, Inc. (AMRX)
sacituzumab govitecan	Phoenix Life Sciences International Limited. (PLSI)
tak-280	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-280	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
temozolomide	ENANTA PHARMACEUTICALS INC (ENTA)
tislelizumab	BeOne Medicines Ltd. (ONC)
vinflunine	Phoenix Life Sciences International Limited. (PLSI)
zolbetuximab	Merus N.V. (MRUS)
zongertinib	Merus N.V. (MRUS)

Phase 2(9)

Drug	Company
Budigalimab	AbbVie Inc. (ABBV)
CAPOX	Merus N.V. (MRUS)
FOLFOX	ENANTA PHARMACEUTICALS INC (ENTA)
Fosifloxuridine Nafalbenamide	IGM Biosciences, Inc. (IGMS)
Ifinatamab Deruxtecan	Merus N.V. (MRUS)
Leucovorin	AbbVie Inc. (ABBV)
Patritumab Deruxtecan	Merus N.V. (MRUS)
Tripegfilgrastim	KYNTRA BIO INC. (KYNB)
Tuvusertib	Merck & Co., Inc. (MRK)

Phase 1(31)

Drug	Company
ATG-022	Merck & Co., Inc. (MRK)
AU-007	ENANTA PHARMACEUTICALS INC (ENTA)
CAPOX	Merck & Co., Inc. (MRK)
EO-3021	Elevation Oncology, Inc. (ELEV)
EO-3021 (also known as SYSA1801 or CPO102)	Elevation Oncology, Inc. (ELEV)
FOLFIRI	BridgeBio Oncology Therapeutics, Inc. (BBOT)
FOLFIRI	REGENXBIO Inc. (RGNX)
FOLFIRI	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFOX	REGENXBIO Inc. (RGNX)
FOLFOX	BridgeBio Oncology Therapeutics, Inc. (BBOT)
hro761	Novartis AG (NVS)
hro761	NOVARTIS AG (NVSEF)
IL-2	BioNTech SE (BNTX)
JNJ-89402638	IGM Biosciences, Inc. (IGMS)
JNJ-89402638	ENANTA PHARMACEUTICALS INC (ENTA)
JNJ-89402638	REGENXBIO Inc. (RGNX)
JNJ-89402638	Merus N.V. (MRUS)
JNJ-89402638	BridgeBio Oncology Therapeutics, Inc. (BBOT)
NEO-PTC-01	BioNTech SE (BNTX)
PD-1 Inhibitors	BioNTech SE (BNTX)
Pumitamig	Merus N.V. (MRUS)
ST101	PTC THERAPEUTICS, INC. (PTCT)
ST101	Royalty Pharma plc (RPRX)
ST101	Merus N.V. (MRUS)
ST101	Janux Therapeutics, Inc. (JANX)
ST101	Myovant Sciences Ltd. (MYOV)
tcellvax	Regen BioPharma Inc (RGBPP)
Temozolomide	Janux Therapeutics, Inc. (JANX)
Temozolomide	Myovant Sciences Ltd. (MYOV)
Temozolomide	Royalty Pharma plc (RPRX)
Zavedos®	Merus N.V. (MRUS)

Unknown(2)

Drug	Company
OOS AMTAGVI	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
tafinlar/mekinist	Novartis AG (NVS)

BLA Filed(1)

Drug	Company
larotrectinib	LOXO ONCOLOGY, INC. (LOXO)

Phase 1/Phase 2(9)

Drug	Company
[203pb]vmt-α-net	Perspective Therapeutics, Inc. (CATX)
[212pb]vmt-α-net	Perspective Therapeutics, Inc. (CATX)
IOV-3001	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
iov-4001	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
mrtx1719	Mirati Therapeutics, Inc. (MRTX)
phase 1b	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
REC-1245	RECURSION PHARMACEUTICALS, INC. (RXRX)
VMT-α-NET	Perspective Therapeutics, Inc. (CATX)
will receive hh-009	China Health Industries Holdings, Inc. (CHHE)

Phase 2/Phase 3(5)

Phase 4(1)

Drug	Company
IBI363 + Chemotherapy	Merus N.V. (MRUS)

BioSniper tracks 105 drugs in development for Unresectable across 43 companies.

There are 1 clinical trial targeting Unresectable tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.